AbbVie's Humira nabs orphan status in skin disease; GSK-backed poll boosts case for meningitis vaccines;

> AbbVie's ($ABBV) top-selling anti-inflammatory therapy Humira won an FDA orphan designation in the rare skin disease hidradenitis, making the drug eligible for 7 years of exclusivity in that indication. Report

> A new U.S. poll found that 83% of parents want their teens and young adults to be vaccinated against meningococcal disease; the survey was sponsored by GlaxoSmithKline ($GSK), which markets the men B shot Menhibrix. Release

> A generics maker is suing the FDA after the agency declared that its version of the Johnson & Johnson ($JNJ) ADHD med Concerta wasn't bioequivalent to the brand, nixing the copycat med's automatic substitution at pharmacies. Report

> The first set of American Urological Association guidelines for Peyronie's disease, in which scar tissue builds up in the penis, recommends Endo's ($ENDP) Xiaflex as a treatment option. Release

> Makovsky's health practice director Gil Bashe jumped ship to join rival PR firm Finn Partners, where he'll focus on growing the firm's business in biopharma. Report

> The health-focused communications agency KYNE recruited Novartis ($NVS) vet Maureen Byrne to head up its New York office. Report

And Finally... Merck KGaA could have trouble hitting healthcare heights. Report (sub. req.)

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Sanofi and Regeneron's blockbuster Dupixent is eyeing an approval in eosinophilic esophagitis after cutting patients' difficulty breathing.